Aprea Therapeutics (NasdaqCM:APRE) FY Conference February 26, 2026 08:40 AM ET Company ParticipantsOren Gilad - President and CEONone - AssociateNoneMorning, everyone, thanks for joining us. My name is Anthony, and I'm an associate here at Oppenheimer. It's my pleasure to introduce Aprea Therapeutics, a precision oncology company focused on targeting the DNA damage response pathway. Their lead program is APRN-1051, a next-gen WEE1 inhibitor. The company is also advancing ATRN-119, a macrocyclic ATR inhibito ...